Dr. Monika Davare is a cancer biologist with expertise in molecular pharmacology and training in neurobiology. Her research is dedicated to improving outcomes for patients with rare and aggressive pediatric and adult cancers, including Ewing's sarcoma, glioblastoma, pediatric high-grade glioma and non-smoking lung cancer.

Drawing from her extensive knowledge of receptor biology and kinase signaling, the Davare laboratory investigates how mutations, gene fusions and other oncogenic mechanisms disrupt cellular signaling pathways, promoting tumor growth and treatment resistance. Laboratory efforts focus on understanding the mechanistic underpinnings of rare oncogene-driven cancers, translating challenging genetic discoveries—including variants of uncertain significance—into actionable therapeutic strategies.

Through strong interdisciplinary collaborations and using patient-derived tumor models, structural biochemistry and advanced drug screening approaches, Dr. Davare works closely with clinicians and industry partners to accelerate therapeutic innovations and the development of personalized treatments. Her goal is to bridge fundamental biological discoveries with tangible clinical solutions that directly impact patient care, offering new hope to patients and families affected by these complex malignancies.

To help advance our research, please consider supporting us.  You can make a gift online.